Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Suit: Amgen underpaid royalties
While Northwestern swims like Scrooge McDuck in its $700 million Lyrica payment, Sloan-Kettering Institute for cancer research is suing Amgen for underpaying royalties by more than $72 million. The cancer center claims that, when calculating royalties, Amgen deducted Aranesp-related rebates from Neupogen and Neulasta sales. The latter two drugs sold at a rate of $1.1 billion just in the third quarter. Amgen denies the claims.
- check out this report
- read the Pharmalot item
Related Articles:
Northwestern sells Lyrica rights for $700M. Report
Lyrica OK'd for epilepsy. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
